TechnologieAllianz is the German association for knowledge and technology transfer (KTT) and brings together universities, national research institutions and transfer service providers in a nationwide network. TechnologieAllianz is promoting the development and recognition of the KTT profession in Germany and is also striving towards sharing best…
End of last year, Dr Claus Schulte joined Ascenion’s team in Munich as Project and Start-up Manager. He draws on many years’ experience in the life-sciences industry, in technology transfer and the start-up scene. He led various business development and licensing departments and gained experience in founding and managing start-up companies.
Claus…
At the end of January, 19 technology transfer specialists representing Ascenion’s partner institutions in Germany and Austria gathered in Munich for the company’s dedicated TT-workshop. The workshop represents a unique platform for Ascenion’s partners to share experiences from the various research organizations and expand their TT-know-how in a…
This year’s Annual Meeting of TechnologieAllianz, Germany’s association for knowledge and technology transfer (KTT) will take place on 20-21 March 2019 in Frankfurt, Germany. For the first time, it has been extended to two days providing extra dedicated time for international networking and program highlights.
Gain valuable insights from…
BioVaria is organised by Ascenion and several other technology transfer organisations from all across Europe. The conference brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international biopharmaceutical industry. Top-tier academic institutions and universities from all…
This year’s Annual Meeting of TechnologieAllianz, Germany’s association for knowledge and technology transfer (KTT), will take place on 20-21 March 2019 in Frankfurt, Germany. For the first time, it has been extended to two days providing extra dedicated time for international networking and program highlights.
Gain valuable insights from…
Ascenion Negotiated Additional Licence Agreement between Helmholtz Zentrum München and Medigene
9 January 2019, Munich – The Helmholtz Zentrum München and Medigene have closed a licence agreement providing the company with exclusive rights to a chimeric co-stimulatory receptor for therapeutic and diagnostic applications in the field of T-cell…
Three months following the first closing of its Series C financing, iThera Medical completed a second closing with Occident Ventures, BayBG and Falk Strascheg Holding raising the total volume of Series C by EUR 2 million to a total of EUR 9 million. Investors of the first closing include FLUXUNIT, the corporate venture capital arm of OSRAM, the…
We would like to thank all our clients, colleagues and partners in technology transfer, research and industry for the enjoyable and productive collaboration over the past year.
Instead of sending Christmas cards, we have decided to make a donation to the Förderverein Kinderpalliativzentrum München e. V. (www.fvkp.de). This charity supports the…
Agreement with Max Delbrück Center Provides Access to Broad Intellectual Property Portfolio of Unique Humanized Antibody Fragments and Antigen-Binding Domains Targeting BCMA.
Ascenion GmbH, technology transfer partner of the Max Delbrück Center for Molecular Medicine (MDC), has negotiated an agreement between the MDC and Fate Therapeutics, Inc.,…
Clinicians and scientists from the Medical University Innsbruck (MUI) and the University of Innsbruck have developed an innovative urine test to determine electrolyte balance. The intellectual property rights to the underlying technology have been licensed exclusively to the start-up UriSalt, which will further develop and commercialize the…
Don’t miss your chance to secure a spot at next year’s BioVaria, 8 - 9 May 2019 in Munich! Application for European startups is now open until 1st March 2019. Selected teams and companies will benefit from the two-day Startup Pitch & Partner program designed to promote your business amongst life-science investors and pharma executives and to…
Following the successful completion of a Phase I trial with its cardioprotective lead candidate OMT-28, OMEICOS has now closed a Series C financing led by new investor Forbion. The existing investors Vesalius Biocapital II S.A. SICAR, Remiges BioPharma Fund, SMS group GmbH, KFW Group, VC Fonds Technologie Berlin, High-Tech Gründerfonds II GmbH…
This year’s technology transfer award from Braunschweig’s Chamber of Industry and Commerce goes to scientists at the Helmholtz Centre for Infection Research (HZI) and its spin-off company InSCREENeX. Together, they have developed technologies for the rapid and cost-efficient production of cell lines with tissue-like characteristics that enable…
iThera Medical, a spin-off from the Helmholtz Zentrum München, has closed series C financing with new investors FLUXUNIT, the corporate venture capital arm of OSRAM, and the Wachstumsfonds Bayern. The current investors BayBG and Extorel co-invested in the round. The company will use the funds of over EUR 7 million to accelerate and expand the…
Amgen announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO® (blinatumomab) for the treatment of certain forms of B cell acute lymphoblastic leukaemia (ALL). BLINCYTO is a bispecific antibody that helps the body’s immune system target cells of B cell lineage. It connects B cells expressing…
Ascenion’s partner institute, the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI), has joined forces with the Friedrich Schiller University Jena and other partners to form a new Cluster of Excellence “Balance of the Microverse”. Its focus is on the study of complex microbial communities that are important in many…
Shire’s VEYVONDI received EU market authorization for the treatment of bleeding events and the prevention or treatment of surgical bleeding in adults with von Willebrand disease (VWD), the most common inherited bleeding disorder. It affects up to one percent of the global population. The product, which has been approved in the US more than two…
